Page last updated: 2024-11-05

isopentenyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isopentenyladenosine (iPA) is a cytokinin, a class of plant hormones that regulate growth and development. It is a naturally occurring compound found in plants, bacteria, and fungi. iPA is synthesized from adenosine monophosphate (AMP) through a series of enzymatic steps. It exerts its effects by binding to specific receptors, leading to the activation of downstream signaling pathways. iPA plays a crucial role in various plant processes, including cell division, differentiation, and organogenesis. It promotes root and shoot growth, delays leaf senescence, and influences flowering time. iPA has also been shown to have biological activities in animals, including immune modulation and anti-inflammatory effects. Its potential applications in agriculture and medicine are being investigated, making it a subject of ongoing research.'
```

Isopentenyladenosine: N(6)-[delta(3)-isopentenyl]adenosine. Isopentenyl derivative of adenosine which is a member of the cytokinin family of plant growth regulators. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(6)-(Delta(2)-isopentenyl)adenosine : A nucleoside analogue in which adenosine has been modified by substitution at the 6-amino nitrogen by a Delta(2)-isopentenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24405
CHEMBL ID452867
CHEBI ID62881
SCHEMBL ID4599
MeSH IDM0011777

Synonyms (79)

Synonym
nsc-105546
isopentenyladenosine riboside
2-ipa
9beta-d-ribofuranosyl-9h-purine, n-(3-methyl-2-butenylamino)-
nsc 105546
riboprina [inn-spanish]
n(sup 6)-(2-isopentenyl)adenosine
einecs 231-771-3
6-n-((3-methyl-2-butenyl)amino)-9beta-d-ribofuranosylpurine
6-n-((3-methyl-2-butenyl)amino)-9-beta-d-ribofuranosyl-9h-purine
n(sup 6)-dimethylallyladenosine
n(sup 6)-isopentenyladenosine
riboprinum [inn-latin]
riboprine [usan:inn]
6-(gamma,gamma-dimethylallylamino)purine riboside
n(sup 6)-(delta(sup 2)-isopentenyl)adenosine
adenosine, n-(3-methyl-2-butenyl)-
riboprine
7724-76-7
isopentenyladenosine
isopentenyl adenine riboside
n-(3-methyl-2-butenyl)adenosine
n6-(2-isopentenyl)adenosine
n6-(3-methyl-2-butenyl)adenosine
sq 22558
n6-isopentenyladenosine
dimethylallyladenosine
2ipa
6-(3-methyl-2-butenylamino)purine riboside
zk 20 242
riboprine (usan/inn)
D05726
isopentenyl adenosine
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(3-methylbut-2-enylamino)purin-9-yl]oxolane-3,4-diol
chebi:62881 ,
CHEMBL452867
n6-(2-isopentenyl)-adenosine
n(6)-(2-isopentenyl)adenosine
n(6)-(3-methyl-2-butenyl)adenosine
riboprinum
riboprina
n(6)-(delta(2)-isopentenyl)adenosine
n-(3-methylbut-2-en-1-yl)adenosine
n-(3-methylbut-2-enyl)adenosine
i6a ,
unii-8eu82faz5j
8eu82faz5j ,
AKOS016009606
riboprine [inn]
6-n-((3-methyl-2-butenyl)amino)-9-.beta.-d-ribofuranosyl-9h-purine
riboprine [usan]
SCHEMBL4599
NCGC00253650-01
dtxsid1057828 ,
dtxcid2031617
tox21_113776
cas-7724-76-7
riboprin
n6-(.gamma.,.gamma.-dimethylallyl)adenosine
USVMJSALORZVDV-SDBHATRESA-N
n6-(.delta.2-isopentenyl)adenine riboside
n6-dimethylallyladenosine
6-n-((3-methyl-2-butenyl)amino)-9.beta.-d-ribofuranosylpurine
CS-W011925
mfcd00005741
sr-01000883994
SR-01000883994-1
DB11933
DS-5147
2ip riboside
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-((3-methylbut-2-en-1-yl)amino)-9h-purin-9-yl)tetrahydrofuran-3,4-diol
Q973089
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-(3-methylbut-2-enylamino)-9h-purin-9-yl)tetrahydrofuran-3,4-diol
6-( gamma , gamma -dimethylallylamino)purine riboside
n6-(3,3-dimethylallylamino)purine riboside
ribosyl-deoxyzeatin
HY-W011209
adenosine, n-(3-methyl-2-buten-1-yl)-
BP-58623

Research Excerpts

Overview

N6-isopentenyladenosine (iPA) is an anti-proliferative and pro-apoptotic atypical nucleoside for normal and tumor cells. N(6)A is a product of isopENTenyltransferases and, in mammals, occurs either bound to tRNA or as a free nucleosides.

ExcerptReferenceRelevance
"N6-isopentenyladenosine (iPA) is an intermediate of the mevalonate pathway that exhibits various anti-cancer effects. "( The isoprenoid end product N6-isopentenyladenosine reduces inflammatory response through the inhibition of the NFκB and STAT3 pathways in cystic fibrosis cells.
Bifulco, M; Capunzo, M; Ciaglia, E; Nicolin, V; Nori, SL; Pescatore, A; Prota, L; Santoro, A; Ursini, MV, 2018
)
1.39
"N6-isopentenyladenosine is an anti-proliferative and pro-apoptotic atypical nucleoside for normal and tumor cells. "( N6-isopentenyladenosine a new potential anti-angiogenic compound that targets human microvascular endothelial cells in vitro.
Casati, S; Castiglioni, S; Ciuffreda, P; Maier, JAM; Ottria, R; Perrotta, C; Romeo, V, 2018
)
1.72
"N6-isopentenyladenosine (iPA) is a modified adenosine with an isopentenyl moiety derived from the mevalonate pathway which displays pleiotropic biological effects, including anti-tumor and anti-angiogenic activity. "( N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.
Bifulco, M; Ciaglia, E; Gazzerro, P; Laezza, C; Malfitano, AM; Picardi, P; Pisanti, S; Sosa, S; Tubaro, A; Vitale, M, 2014
)
1.65
"N(6)-isopentenyladenosine (i6A) is a modified nucleoside with a pentaatomic isopentenyl derived from mevalonate that induces inhibition of tumor cell proliferation and apoptosis in several tumor cell lines. "( N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1.
Bifulco, M; Caruso, MG; Di Matola, T; Gazzerro, P; Gentile, T; Laezza, C; Malfitano, AM; Messa, C; Notarnicola, M, 2009
)
1.49
"N(6)-Isopentenyladenosine (iPA) is a member of the cytokinins, a family of plant hormones that regulate plant cell growth and differentiation. "( Antiproliferative activity of N6-isopentenyladenosine on MCF-7 breast cancer cells: cell cycle analysis and DNA-binding study.
Ghidoni, R; Gorincioi, E; Rajabi, M; Santaniello, E; Signorelli, P, 2010
)
1.16
"Isopentenyladenosine (i(6)A) is a product of isopentenyltransferases and, in mammals, occurs either bound to tRNA or as a free nucleoside. "( N6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers.
Colombo, F; Dragani, TA; Falvella, FS; Spinola, M, 2007
)
2.4

Actions

ExcerptReferenceRelevance
"N6-Isopentenyladenosine plays a major role in posttranscriptional processes, including the function of mammalian selenocysteine tRNA."( Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug.
Bifulco, M; Caruso, MG; Laezza, C; Malfitano, AM; Proto, MC; Santoro, A, 2008
)
1.12

Toxicity

ExcerptReferenceRelevance
"Due to their widespread distribution and toxic nature, herbicides may have a serious impact on the environment and exert adverse effects on associated organisms."( Comparative study of plant growth hormone (herbicide) toxicity in various biological subjects.
Fargasová, A, 1994
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
"Pentostatin (I), a tight-binding inhibitor of adenosine deaminase, was evaluated in combination with the partially effective antitumor nucleoside N6-(delta 2-isopentenyl)adenosine (II) for cytotoxic activity against cultured L-1210 lymphocytic mouse leukemia cells."( Increased cytotoxicity of N6-(delta 2-isopentenyl)adenosine in combination with pentostatin against L-1210 leukemia cells.
Chang, Y; Hacker, B, 1983
)
0.27
"The use of the aqueous extracts of Eleutherococcus senticosus in combination with either cytarabine or N6-(delta 2-isopentenyl)-adenosine gave additive antiproliferative effects against L1210 murine leukemia."( Cytotoxic effects of Eleutherococcus senticosus aqueous extracts in combination with N6-(delta 2-isopentenyl)-adenosine and 1-beta-D-arabinofuranosylcytosine against L1210 leukemia cells.
Hacker, B; Medon, PJ, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The investigation of gene dosage effects in homozygote plants readdresses the question of threshold levels for cytokinin effects on the developmental program of plants."( Promoter tagging with a promoterless ipt gene leads to cytokinin-induced phenotypic variability in transgenic tobacco plants:implications of gene dosage effects.
Hewelt, A; Prinsen, E; Schell, J; Schmülling, T; Van Onckelen, H, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
plant growth regulatorA chemical, natural or artificial, that can affect the rate of growth of a plant.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
N-ribosyl-N(6)-isopentenyladenine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Regulation of leaf development1722
Cytokinins Degradation113
cytokinins degradation114
cytokinins degradation519
Trans-zeatin biosynthesis022

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency15.58753.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency9.32060.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency3.85780.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency16.28380.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency16.78550.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency7.69750.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency18.65520.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.76780.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency3.01070.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.35830.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency9.43920.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.32860.000229.305416,493.5996AID1259244; AID1259248
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.70830.001019.414170.9645AID743191
caspase-3Homo sapiens (human)Potency16.78550.013326.981070.7614AID1346978
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency26.832519.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency60.19930.039147.5451146.8240AID1224845; AID1224896
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency3.05650.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency3.34910.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency7.45360.00339.158239.8107AID1347407
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency3.34910.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)IC50 (µMol)5,000.00006.00007.33338.0000AID75595
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
microtubule cytoskeleton organizationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
positive regulation of cytokine productionGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
glucose metabolic processGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
glycolytic processGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
negative regulation of endopeptidase activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
regulation of macroautophagyGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
negative regulation of translationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
killing of cells of another organismGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
positive regulation of type I interferon productionGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
peptidyl-cysteine S-trans-nitrosylationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
protein stabilizationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
defense response to fungusGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
neuron apoptotic processGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
killing by host of symbiont cellsGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cellular response to type II interferonGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
protein bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
microtubule bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
aspartic-type endopeptidase inhibitor activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
peptidyl-cysteine S-nitrosylase activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
identical protein bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
NADP bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
NAD bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
disordered domain specific bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
RNA bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
protein bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
dimethylallyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cytoplasmGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
lipid dropletGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cytosolGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
plasma membraneGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
microtubule cytoskeletonGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
membraneGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
nuclear membraneGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
vesicleGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
perinuclear region of cytoplasmGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
extracellular exosomeGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
GAIT complexGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
ribonucleoprotein complexGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cytosolGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
nucleoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytosolFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1293510Cytotoxicity against human RD cells2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID1162561Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) assessed as binding constant of proton H11 of isopentenylic moiety by saturation transfer difference NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID486632Antiproliferative activity against quiescent human T24 cells at 10 uM after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Synthesis and evaluation of in vitro anticancer activity of some novel isopentenyladenosine derivatives.
AID486631Cytotoxicity against human T24 cells assessed as inhibition of cell colony formation at 10 uM after 24 hrs by crystal violet staining2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Synthesis and evaluation of in vitro anticancer activity of some novel isopentenyladenosine derivatives.
AID1162557Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) at protein/ligand 1:10 to 1:100 molar ratio by WaterLOGSY NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID1175339Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Naturally occurring N(6)-substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: an in silico evaluation of their interaction with the P2Y(12) receptor.
AID75707Inhibition of Leishmania mexicana GAPDH(glyceraldehyde-3-phosphate dehydrogenase)1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Synthesis and structure-activity relationships of adenosine analogs as inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase. Modifications at positions 5' and 8.
AID1162556Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) at protein/ligand 1:10 to 1:100 molar ratio by saturation transfer difference NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID1293511Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 712016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID75708Inhibitory activity was measured for Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in Leishmania. mexicana at 10 mM1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID1430043Cytotoxicity against PEK cells after 24 hrs2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1430044Cytotoxicity against PEK cells after 7 days2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1430042Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1162558Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) at protein/ligand 1:10 to 1:100 molar ratio by WaterLOGSY 1D 1H NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID1430041Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction at 50 uM preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1162563Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) at protein/ligand 1:10 to 1:100 molar ratio by 2D COSY NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID1162559Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) assessed as binding constant of proton H2/H8 of purine ring by saturation transfer difference NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID486638Antimetastatic activity in human T24 cells assessed as inhibition of EGF-stimulated cellular migration at 10 uM after 16 hrs by microscopic analysis2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Synthesis and evaluation of in vitro anticancer activity of some novel isopentenyladenosine derivatives.
AID1162560Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) assessed as binding constant of proton H12 of isopentenylic moiety by saturation transfer difference NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID75595Inhibitory activity measured for Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in Leishmania. mexicana1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design.
AID1162562Binding affinity to FPPS (unknown origin) expressed in Escherichia coli BL21(DEscherichia ) assessed as binding constant of proton H14-H15 of isopentenylic moiety by saturation transfer difference NMR analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
AID1293509Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (310)

TimeframeStudies, This Drug (%)All Drugs %
pre-199072 (23.23)18.7374
1990's43 (13.87)18.2507
2000's70 (22.58)29.6817
2010's102 (32.90)24.3611
2020's23 (7.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.39 (24.57)
Research Supply Index5.77 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index30.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.31%)5.53%
Reviews12 (3.77%)6.00%
Case Studies1 (0.31%)4.05%
Observational0 (0.00%)0.25%
Other304 (95.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]